ImmunityBio shares are trading higher after the company presented long-term overall survival data in non-small cell lung cancer patients and announced registrational intent Phase 3 trials with ANKTIVA and checkpoint immunotherapy at the World Conference on Lung Cancer.
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio shares rose following the presentation of positive long-term survival data for non-small cell lung cancer patients and the announcement of Phase 3 trials with ANKTIVA and checkpoint immunotherapy.
September 09, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunityBio's stock is up due to positive long-term survival data in lung cancer and upcoming Phase 3 trials with ANKTIVA.
The announcement of positive long-term survival data and new Phase 3 trials is likely to boost investor confidence, leading to a short-term increase in ImmunityBio's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100